Sarepta reports preliminary Q4 2024 net product revenue $638.2M, FY2024 $1.79B, beating guidance by $100M+

Sarepta Therapeutics, Inc.

2024-FY EPS reported $2.34 revenue$1,901,979,000

Preliminary total net product revenue Q4 2024 $638.2M, FY2024 $1.79B, exceeding full-year guidance by over $100M.
ELEVIDYS net product revenue Q4 2024 $384.2M (up 112% sequential), FY2024 $820.8M.
RNA-based PMO net product revenue Q4 2024 $254.0M, FY2024 $967.2M, grew YoY.
Cash, cash equivalents, and investments ~$1.5B as of Dec 31, 2024.
Reiterated 2025 full-year net product revenue guidance of $2.9-3.1B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.